Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 6pembrolizumab 5toripalimab 2fludarabine 2Valproic Acid 2Valganciclovir 2Injections 2Cyclophosphamide 2Cisplatin 2130-nm albumin-bound paclitaxel 2tislelizumab 1spartalizumab 1sapropterin 1fosaprepitant 1fludarabine phosphate 1camrelizumab 1Surgical Procedures, Operative 1Specimen Handling 1SHR-1701 1Protons 1Proton Therapy 1Panobinostat 1Medicare Part B 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Floxuridine 1Everolimus 1Dexamethasone 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Nasopharyngeal Carcinoma × Medicare Part B × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡